# Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

> **NCT05030025** · EARLY_PHASE1 · COMPLETED · sponsor: **Mylan Inc.** · enrollment: 43 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **COMBINATION_PRODUCT:** abacavir, dolutegravir and lamivudine dispersible tablets
- **COMBINATION_PRODUCT:** Triumeq Dispersible Tablets 5 mg GSK1349572 [Dolutegravir]/ 60 mg Abacavir/ 30 mg Lamivudine

## Key facts

- **NCT ID:** NCT05030025
- **Lead sponsor:** Mylan Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-01
- **Primary completion:** 2021-08-29
- **Final completion:** 2021-08-29
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2022-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05030025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05030025, "Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05030025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*